Newest Short Interest Filing: Could Viveve Medical Incorporated (NASDAQ:VIVE) Skyrocket? The Stock Has Too Many Sellers

November 21, 2016 - By Linda Rogers   ·   0 Comments

Newest Short Interest Filing: Could Viveve Medical Incorporated (NASDAQ:VIVE) Skyrocket? The Stock Has Too Many Sellers

The stock of Viveve Medical Incorporated (NASDAQ:VIVE) registered an increase of 153.57% in short interest. VIVE’s total short interest was 28,400 shares in November as published by FINRA. Its up 153.57% from 11,200 shares, reported previously. With 53,300 shares average volume, it will take short sellers 1 days to cover their VIVE’s short positions. The stock increased 4.73% or $0.3 on November 18, hitting $6.64. Viveve Medical Inc (NASDAQ:VIVE) has declined 1.63% since April 19, 2016 and is downtrending. It has underperformed by 5.49% the S&P500.

Viveve Medical, Inc., formerly PLC Systems, Inc., designs, develops, makes and markets medical devices for the non-invasive treatment of vaginal laxity. The company has a market cap of $74.05 million. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. It currently has negative earnings. The Viveve System uses monopolar radiofrequency energy to generate low temperature heat.

VIVE Company Profile

Viveve Medical, Inc., formerly PLC Systems, Inc., incorporated on March 1, 1999, designs, develops, makes and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. The Viveve System uses monopolar radiofrequency (RF) energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer. The RF energy stimulates the formation of collagen and causes the collagen fibers to remodel thereby tightening the submucosal tissue of the vaginal introitus. The RF stimulation causes subtle alterations in the collagen that can renew the tissue and further tighten the vaginal tissue over the next 1 to 3 months following treatment (the Viveve Treatment) and lead to increased sexual function.

More recent Viveve Medical Inc (NASDAQ:VIVE) news were published by: Marketwatch.com which released: “Viveve Medical” on November 25, 2013. Also Streetinsider.com published the news titled: “Viveve Medical (VIVE) Files Patent Infringement Lawsuit Against Thermi in Texas” on October 21, 2016. Seekingalpha.com‘s news article titled: “Viveve Medical on deck for IPO” with publication date: May 25, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>